Financial Performance - The company achieved operating revenue of CNY 220,598,316.50, a year-on-year increase of 32.72%[4] - Net profit attributable to shareholders reached CNY 69,473,315.06, up 36.89% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 62,550,848.63, reflecting a growth of 43.68%[4] - Basic earnings per share were CNY 0.69, representing a 32.69% increase year-on-year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 727,765,387.92, a 3.49% increase from the beginning of the period[4] - Shareholders' equity attributable to the company was CNY 703,460,878.06, up 7.79% year-on-year[4] - The company's total share capital increased to 100,000,000, a 25% rise from the previous period[4] - The net asset per share attributable to shareholders decreased to CNY 7.03, a decline of 13.85% year-on-year[5] Specific Revenue Sources - The sales revenue from sulfonamide raw materials was approximately CNY 15,000,000, increasing by about 50% due to improved conditions in the downstream aquaculture industry[6] Return on Investment - The company's weighted average return on net assets (after deducting non-recurring items) was 9.25%[4]
海昇药业(920656) - 2025 Q4 - 年度业绩